ArticleJournal of translational medicine2025
Sequential PD-1 inhibitors as consolidative therapy post-CD19 CART in relapsed/refractory NHL: a propensity score matching cohort study.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of baseline immune cell composition with CAR-T cell expansion and survival in Relapsed/Refractory large B-Cell lymphoma.Journal of translational medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundCD19-directed chimeric antigen receptor T-cell therapy (CART) has improved outcomes for relapsed/refractory non-Hodgkin lymphoma (R/R NHL). However, patients with high-risk molecular features, such as double-expressor lymphoma (DEL+), characterized by concurrent MYC and BCL-2 protein overexpression, and TP53 alterations (TP53+), experience dismal outcomes with CART alone.
methodsThis single-center, propensity score matching (PSM) cohort study analyzed 44 R/R NHL patients. 22 patients received consolidative PD-1 inhibitors (Sintilimab, iPD-1) after CART, matched 1:1 with 22 patients receiving CART alone based on 10 baseline characteristics.
resultsThe CART + iPD-1 group showed significantly improved progression-free survival (PFS, median 42.9 months vs. 3.0 months; HR = 0.32, P = 0.003) and overall survival (OS, median not reached vs. 21.5 months; HR = 0.24, P = 0.017). Disease recurrence (40.9% vs. 81.8%, P = 0.013) and progression-related mortality (13.6% vs. 54.5%, P = 0.011) were markedly reduced. The DEL+TP53+ subgroup benefited most (PFS P < 0.001, OS P = 0.010). Adverse events, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), were comparable between groups.
conclusionConsolidative PD-1 inhibitors following CD19 CART infusion could improves survival outcomes in R/R NHL, particularly for the high-risk DEL+TP53+ population, without adding significant toxicity. This suggests a molecularly-defined approach to consolidation therapy and emphasizes the importance of strategic timing in combination immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.